Search results for: 'scienc companion partnering 2025 2016'

Companion Diagnostics Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2010 to 2025

Provides a detailed understanding and analysis of how and why companies enter Big Pharma partnering deals

The Leading Partnering Intelligence Platform for Pharma, Biotech and Diagnostic Dealmakers

The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2026) report offers in-depth insights and exclusive access to preclinical-stage partnering agreements signed by the world’s leading biopharma companies, providing a detailed analysis of deal structures, financial terms and strategic collaborations.

The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2026) report offers in-depth insights and exclusive access to discovery-stage partnering agreements signed by the world’s leading biopharma companies, providing a detailed analysis of deal structures, financial terms and strategic collaborations.

The Clinical Stage Partnering Terms and Agreements in Pharma and Biotech report offers in-depth insights and exclusive access to clinical-stage partnering agreements signed by the world’s leading biopharma companies, providing a detailed analysis of deal structures, financial terms and strategic collaborations.

Specialty Pharmaceutical Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter specialty pharmaceutical partnering deals. 

Global Biotech Partnering Terms and Agreements 2018 to 2023 report provides a detailed understanding and analysis of how and why companies enter biotech partnering deals.

Provides comprehensive understanding and unprecedented access to the animal health agreements entered into by the world's leading biopharma companies.

Global Generic Pharmaceutical Partnering Terms and Agreements 2010 to 2026 report provides a detailed understanding and analysis of how and why companies enter generic pharmaceutical partnering deals.